NCT02862938View on ClinicalTrials.gov

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 15, 2025

Study Completion Date

December 15, 2025

Conditions
Glaucoma
Interventions
DRUG

NT-501 ECT implant

NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.

OTHER

Sham

Sham surgery

Trial Locations (1)

94303

Byers Eye Institute at Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT02862938 - Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration | Biotech Hunter | Biotech Hunter